Literature DB >> 4693651

The glucose receptor. A defective mechanism in diabetes mellitus distinct from the beta adrenergic receptor.

R P Robertson, D Porte.   

Abstract

Acute serum insulin responses in 10 normal subjects after rapid intravenous injection of glucose (5 g) or isoproterenol (2 mug) were of similar magnitude and timing (glucose: 431+/-349%; mean Delta3-5' insulin (IRI)+/-SD, per cent basal and isoproterenol: 359+/-216%; mean Delta2-4' IRI+/-SD, per cent basal). To elucidate the relationship of glucose-induced insulin secretion to pancreatic beta adrenergic receptors and the implications of this relationship with regards to abnormal insulin secretion in diabetes mellitus, two questions were studied. (a) To determine whether glucose-induced insulin secretion is dependent upon beta adrenergic activity, the effect of beta adrenergic blockade with intravenous propranolol (0.08 mg/min) upon acute insulin responses to isoproterenol and glucose were compared in normal subjects. (b) To determine whether acute insulin responses to beta adrenergic stimulation were intact in diabetes mellitus, the effect of isoproterenol upon serum insulin levels was studied in diabetic subjects. Beta adrenergic blockade in the normal subjects obliterated acute insulin responses to isoproterenol (before: 361+/-270%, during: - 31+/-15%; n = 6, P < 0.001) but did not significantly affect responses to glucose (before; 311+/-270%; during: 284+/-206%; n = 5). The mean acute insulin response after isoproterenol in the diabetic group was significantly elevated over basal levels (152+/-74%; n = 10, P < 0.001) but the response after glucose was not (- 11+/-11%). These data suggest that insulin responses to glucose in normal subjects are mediated by specific pancreatic glucose receptors which are independent from beta adrenergic receptors and that abnormal glucose-induced insulin secretion in diabetics is due to defects within glucose receptors and not beta adrenergic receptors as has been previously hypothesized.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4693651      PMCID: PMC302334          DOI: 10.1172/JCI107251

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  7 in total

1.  Glucoreceptor mechanisms in islets of Langerhans.

Authors:  F M Matschinsky; R Landgraf; J Ellerman; J Kotler-Brajtburg
Journal:  Diabetes       Date:  1972       Impact factor: 9.461

2.  The effect of an adenosine--3'5'--monophosphate diesterase inhibitor (aminophylline) on the insulin response to glucose infusion in prediabetic and diabetic subjects.

Authors:  E Cerasi; R Luft
Journal:  Horm Metab Res       Date:  1969-07       Impact factor: 2.936

3.  Role of adrenergic receptors in glucose-induced insulin secretion in man.

Authors:  E Cerasi; S Effendic; R Luft
Journal:  Lancet       Date:  1969-08-09       Impact factor: 79.321

4.  Serum insulin following isoprenaline in normal and diabetic persons.

Authors:  T Deckert; U B Lauridsen; S N Madsen; M Deckert
Journal:  Horm Metab Res       Date:  1972-07       Impact factor: 2.936

5.  Effect of adrenergic blocking agents on insulin response to glucose infusion in man.

Authors:  E Cerasi; R Luft; S Efendić
Journal:  Acta Endocrinol (Copenh)       Date:  1972-02

6.  Stimulation of insulin release by glucagon in noninsulin-dependent diabetics.

Authors:  R G Simpson; A Benedetti; G M Grodsky; J H Karam; P H Forsham
Journal:  Metabolism       Date:  1966-11       Impact factor: 8.694

7.  The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects.

Authors:  J D Bagdade; E L Bierman; D Porte
Journal:  J Clin Invest       Date:  1967-10       Impact factor: 14.808

  7 in total
  45 in total

Review 1.  Hypertension: which beta-blocker?

Authors:  H J Waal-Manning
Journal:  Drugs       Date:  1976-12       Impact factor: 9.546

2.  Early metabolic markers that anticipate loss of insulin independence in type 1 diabetic islet allograft recipients.

Authors:  D Hirsch; J Odorico; J S Danobeitia; R Alejandro; M R Rickels; M Hanson; N Radke; D Baidal; D Hullett; A Naji; C Ricordi; D Kaufman; L Fernandez
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

3.  Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations.

Authors:  R P Robertson; H J Zhang; K L Pyzdrowski; T F Walseth
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

4.  Chronic exposure to glibenclamide impairs insulin secretion in isolated rat pancreatic islets.

Authors:  D Gullo; A M Rabuazzo; M Vetri; C Gatta; C Vinci; M Buscema; R Vigneri; F Purrello
Journal:  J Endocrinol Invest       Date:  1991-04       Impact factor: 4.256

5.  Effects of a combination of bedtime intermediate-acting insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to respond to oral hypoglycaemic agents.

Authors:  M Krempf; T Godeau; S Ranganathan; P Blanchard; P Ritz; B Charbonnel
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 6.  Pathogenesis of impaired glucose tolerance and type II diabetes mellitus--current status.

Authors:  M B Davidson
Journal:  West J Med       Date:  1985-02

7.  Insulin and glucagon release in the diabetic Chinese hamster: differences among inbred sublines.

Authors:  B J Frankel; A M Heldt; G M Grodsky
Journal:  Diabetologia       Date:  1982-04       Impact factor: 10.122

8.  Effects of chronic sodium salicylate feeding on the impaired glucagon and epinephrine responses to insulin-induced hypoglycaemia in streptozotocin diabetic rats.

Authors:  D G Patel; K A Skau
Journal:  Diabetologia       Date:  1989-01       Impact factor: 10.122

9.  Abnormal secretion of insulin and glucagon by the in vitro perfused pancreas of the genetically diabetic Chinese hamster.

Authors:  B J Frankel; J E Gerich; R Hagura; R E Fanska; G C Gerritsen; G M Grodsky
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

10.  Effect of vinblastine in vivo on ultrastructure and insulin releasing capacity of the B-cell following sulphonylurea and isopropyl-noradrenaline.

Authors:  L E Ericson; I Lundquist
Journal:  Diabetologia       Date:  1975-10       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.